High‐Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018–2019
In France, high-dose CPA use sharply decreased after the implementation of national regulatory measures without a massive switch to other hormonal therapies. The increase in cerebral imaging screening did not result in an increase in meningioma surgery associated with CPA, but rather a massive drop of over 90%.
Authors
- Isabelle Yoldjian
- Pauline Dayani (ORCID: https://orcid.org/0000-0002-8653-928X)
- Sylvie Fontanel
- Bérangère Baricault (ORCID: https://orcid.org/0000-0001-5835-7668)
- Anke Neumann (ORCID: https://orcid.org/0000-0002-6697-8023)
- Sébastien Froelich (ORCID: https://orcid.org/0000-0001-9124-2395)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Lise Duranteau
- Noémie Roland (ORCID: https://orcid.org/0000-0002-8079-4263)
- Alain Weill (ORCID: https://orcid.org/0000-0001-8687-9092)
Institutions
- Conservatoire National des Arts et Métiers (FR)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (FR)
- Hôpital Lariboisière (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/pds.70078
- Citations
- 5
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Conservatoire National des Arts et Métiers